Frontiers in Viral Hepatitis

Preface.<br>Acknowledgments.<br>Biographies. <br>Contributors. <br>Regulatory Issues, Epidemiology, and Emerging Viruses<br>1. Current issues in the regulation and approval of antiviral drugs for hepatitis (B.A. Styrt, R. Fleischer, T. Wu, H.M. Jolson). <br>2. Molecular and serum epidemiology of HBV and HCV infection and the impact of antiviral agents in China (Xuefeng Liu, R.F. Schinazi). <br>3. New viruses and their relationship to hepatitis (H.J. Alter). <br>Immunology and Vaccines<br>4. Virus-specific CD8+ cell immune responses in acute and chronic hepatitis B virus infection (G.J.M. Webster, G.M. Dusheiko).<br>5. Cell-mediated immunity and the outcome of HCV infection in chimpanzees (C.M. Walker). <br>6. Adoptive immune transfer as a therapeutic approach for persistent hepatitis B virus infection (D. Shouval). <br>7. Perspectives in HCV vaccine development (E. Depla). <br>Viral Hepatitis B and C Infections In Children<br>8. Maternal/fetal/pediatric HBV and HCV infections (R.A. Schreiber). <br>9. Effects of interferon treatment in children with post-transfusional chronic hepatitis B (M. Pop, et al.). <br>Genetics, Pathology and Viral Diagnosis<br>10. Effects of genotypic variations on hepatitis C virus nonstructural protein 5B structure and activity (Zhi Hong, et al.). <br>11. Compartmentalization of hepatitis C viral quasispecies (Xiaofeng Fan, A.C. Lyra, A.M. DiBisceglie). <br>12. In situ localization of PCR-amplified hepatitis C Virus RNA on human erythrocytes (S. Simon, et al.). <br>13. Nucleic acid-based antiviral approaches to HBV (H.C. Spangenberg, J.R. Wands). <br>14. In vitro phenotype of HBV variants in patients with fulminant hepatitis B (M. Sterneck, T. Kalinina). <br>15. Evaluation of three commercially available HBV viral load assays: dynamic range, precision, and clinical utility (A. Snow, F. Myrick, C. Wakeford, B. McCreedy). <br>Cell Systems and Animal Models<br>16. Cell lines that allow regulated expression of HCV proteins: principles and applications (D. Moradpour, et al.).<br>17. Novel Hepatitis C virus-positive cell line derived from a chimpanzee with chronic HCV infection (B.G. Pavlova, Z. Schaff, G. Eder).<br>18. A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus (P.L. Marion, et al.).<br>19. Evaluation of therapies for hepatitis B virus in the HBV transgenic SCID mouse model (M. Kamkolkar, et al.).<br>Drug Discovery and Development: Novel Therapeutics for Hepatitis B and C <br>20. Novel approaches in the management of chronic HBV infection (A. Bartholomeusz, P. Furman, S. Locarnini). <br>21. Antiviral &bgr;-L-nucleosides specific for hepatitis B virus infection (M.L. Bryant, et al.).<br>22. Toxicological study of the anti-HBV agent &bgr;-L-thymidine (E.G. Bridges, et al.).<br>23. Pharmacokinetics of &bgr;-L-thymidine and &bgr;-L-2'-deoxycytidine in woodchucks and monkeys (E. Cretton-Scott, et al.).<br>24. Clevudine: A novel 1-&bgr;-L nucleoside analogue in clinical development for the treatment of HBV infection (G.R. Painter, et al.).<br>25. Glucosidase/protein folding inhibitors as possible mutation proof anti hepatitis B and C agents (T.M. Block, et al.).<br>26. Nuclease resistant ribozymes directed against hepatitis C virus RNA plus and minus strand inhibit viral replication of a HCV/poliovirus chimera (L.M. Blatt, et al.). <br>27. Mechanism of laser therapy of viral hepatitis (V. Ovsiannikov). <br>Drug Discovery and Development: Resistance and Therapeutic Strategies in Humans<br>28. Nomenclature for antiviral resistant human hepatitis B virus mutations in the polymerase region (L.J. Stuyver, et al.).<br>29. Complex genotypic changes during failure of HBV nucleoside analogue therapy (D. Pillay, et al.).<br>30. Lamivudine for chronic hepatitis B: efficacy, safety, resistance, and current treatment issues (N.A. Brown). <br>31. Clinical experience and follow-up with lamivudine in the Asian population (Ching-Lung Lai, Man-Fung Yuen). <br>32. Impaired response to 5 mU/day interferon treatment in African-Americans with chronic hepatitis C (A. Colantoni, N. De Maria, D.H. Van Thiel). <br>33. Novel combined approaches to hepatitis C therapies (M. Cornberg, M.P. Manns). <br>34. Consensus + pegylated interferon (J. Heathcote). <br>35. Impact of interferon alfa-2b and of combination with ribavirin on progression of liver fibrosis in patients with chronic hepatitis C (T. Poynard, et al.).<br>36. Decorin expression in chronic hepatitis C: effect of interferon alpha treatment (I. Kovaloszky, K. J&aacute;rmay, J. Dud&aacute;s, Z. Schaff).<br>37. Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine (G. Painter, L.T. Rimsky et al.).<br>38. CD81 receptor expression in human cells: Implications for HCV therapeutics (P.M. Tharnish, A.S. Juodawlkis et al.). Prevention and Treatment Options for Hepatocellular Carcinoma <br>39. Resolution of hepatic fibrosis as a consequence of interferon therapy for hepatitis C (Y. Shiratori, H. Yoshida, M. Omata). <br>40. Symptomatic therapies for prevention of hepatocellular carcinoma developing in chronic hepatitis C (H. Yotsuyanagi, Y. Miyakawa, S. Lino). <br>41. Mutations of the core gene sequence of HCV from patients with hepatocellular carcinoma in China (T. Omoya, et al.). <br>42. Characterization of hepatitis B virus X variants that are integrated and expressed in human hepatocellular carcinomas (Wei Ning Chen, Chong Jin Oon). Subject Index. Author Index.